7/29/2021 4:10:26 PM
Seagen Q2 Loss/share $0.47 Vs. Loss $0.12 Year Ago
4/29/2021 4:07:55 PM
Seagen Q1 Loss/share $0.67 Vs. Loss $0.98 Year Ago
4/19/2021 8:02:40 AM
Astellas And Seagen Announce FDA Acceptance Of Two Supplemental Biologics License Applications For PADCEV
3/26/2021 2:04:54 AM
Astellas Pharma And Seagen: MAA For Enfortumab Vedotin Accepted By European Medicines Agency
3/5/2021 8:03:08 AM
Seagen Recommends Rejection Of 'Mini-Tender' Offer From TRC Capital Investment
2/18/2021 8:02:16 AM
Astellas And Seagen Submit Two SBLAs To FDA For PADCEV In Locally Advanced Or Metastatic Urothelial Cancer
2/12/2021 6:48:03 AM
Seagen: EC Grants Marketing Authorization For TUKYSA In Combination With Trastuzumab And Capecitabine
2/11/2021 4:07:05 PM
Seagen Q4 EPS $0.90 Vs. $0.14 Year Ago
2/10/2021 4:09:41 PM
Seagen And Genmab A/S Announce Submission Of BLA To FDA Seeking Accelerated Approval For Tisotumab Vedotin
12/11/2020 7:26:15 AM
Seagen Reports Positive CHMP Opinion For TUKYSA For Locally Advanced Or Metastatic HER2-Positive Breast Cancer